BioCentury | Sep 12, 2011
Politics, Policy & Law

Biodefense report card

...attempts to develop better anthrax vaccines. HHS awarded an $877 million contract in 2004 to VaxGen Inc....
...of a recombinant anthrax vaccine. In November 2006, HHS canceled the contract after determining that VaxGen...
...create a special reserve fund to use for countermeasures acquisition from FY04-FY13. Experiences like the VaxGen...
BioCentury | Aug 2, 2010
Company News

diaDexus, VaxGen deal

...a subsidiary of VaxGen (see BioCentury, June 7). diaDexus Inc. , South San Francisco, Calif. VaxGen Inc....
BioCentury | Jun 7, 2010
Company News

diaDexus, VaxGen deal

...The companies amended their previously announced merger. VaxGen will now own about 62% of the combined...
...addressing the heterophilic interference (see BioCentury, April 19). diaDexus Inc. , South San Francisco, Calif. VaxGen Inc....
BioCentury | Apr 19, 2010
Company News

diaDexus, VaxGen deal

...Diagnostic company diaDexus will reverse-merge with VaxGen in a stock deal. diaDexus shareholders will own 60.9%...
...will own 60.9% of the combined company, which will be known as diaDexus Inc., with VaxGen...
...February, VaxGen shareholders rejected a bid by OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN, Waltham, Mass.) to acquire VaxGen...
BioCentury | Apr 19, 2010
Finance

Public at last

...merger with VaxGen Inc . (OTCBB:VXGN), which has been among the walking dead since 2007. VaxGen...
...III trials of a gp120 AIDS vaccine that the big biotech had dropped. Unlike diaDexus, VaxGen...
...NASDAQ:OXGN; SSE:OXGN) in October 2009 - but VaxGen shareholders rejected both deals. In the process, VaxGen's...
BioCentury | Apr 16, 2010
Company News

diaDexus, VaxGen to reverse-merge

...Diagnostic company diaDexus Inc. (South San Francisco, Calif.) will reverse-merge with VaxGen Inc. (OTCBB:VXGN) in a stock...
...shareholders will own 60.9% of the combined company, which will be known as diaDexus, with VaxGen...
...NYSE:EBS) related to VaxGen's rPA102 anthrax vaccine. Emergent acquired the vaccine in 2008. On Thursday, VaxGen...
BioCentury | Apr 5, 2010
Finance

Restructuring Watch

...ATC); a planned acquisition of VaxGen Inc. (OTCBB:VXGN) for about $22.2M in stock falls through after VaxGen...
BioCentury | Feb 15, 2010
Company News

OxiGene, VaxGen deal

...of VaxGen for about $22.2 million stock will not take place after a majority of VaxGen's...
...million against. A vote of 16.6 million in favor was required to approve the acquisition. VaxGen...
...assess other strategic alternatives (see BioCentury, Oct. 19, 2009). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. VaxGen Inc....
BioCentury | Oct 26, 2009
Finance

Ebb & Flow

...Corp. (NASDAQ: GENZ), the only marketed treatment for Fabry's disease in the U.S. Clinical milestones VaxGen Inc....
...III RV144 trial showed that ALVAC HIV vaccine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) boosted by VaxGen's...
BioCentury | Oct 26, 2009
Product Development

Correlates and Endpoints

...HIV, is from the non-profit Global Solutions for Infectious Diseases , which licensed it from VaxGen Inc....
...agencies" like the Bill & Melinda Gates Foundation , NIAID's Vaccine Research Center and IAVI. VaxGen...
...Genentech Inc. , a unit of Roche , to commercialize the vaccine in North America. VaxGen...
Items per page:
1 - 10 of 243
BioCentury | Sep 12, 2011
Politics, Policy & Law

Biodefense report card

...attempts to develop better anthrax vaccines. HHS awarded an $877 million contract in 2004 to VaxGen Inc....
...of a recombinant anthrax vaccine. In November 2006, HHS canceled the contract after determining that VaxGen...
...create a special reserve fund to use for countermeasures acquisition from FY04-FY13. Experiences like the VaxGen...
BioCentury | Aug 2, 2010
Company News

diaDexus, VaxGen deal

...a subsidiary of VaxGen (see BioCentury, June 7). diaDexus Inc. , South San Francisco, Calif. VaxGen Inc....
BioCentury | Jun 7, 2010
Company News

diaDexus, VaxGen deal

...The companies amended their previously announced merger. VaxGen will now own about 62% of the combined...
...addressing the heterophilic interference (see BioCentury, April 19). diaDexus Inc. , South San Francisco, Calif. VaxGen Inc....
BioCentury | Apr 19, 2010
Company News

diaDexus, VaxGen deal

...Diagnostic company diaDexus will reverse-merge with VaxGen in a stock deal. diaDexus shareholders will own 60.9%...
...will own 60.9% of the combined company, which will be known as diaDexus Inc., with VaxGen...
...February, VaxGen shareholders rejected a bid by OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN, Waltham, Mass.) to acquire VaxGen...
BioCentury | Apr 19, 2010
Finance

Public at last

...merger with VaxGen Inc . (OTCBB:VXGN), which has been among the walking dead since 2007. VaxGen...
...III trials of a gp120 AIDS vaccine that the big biotech had dropped. Unlike diaDexus, VaxGen...
...NASDAQ:OXGN; SSE:OXGN) in October 2009 - but VaxGen shareholders rejected both deals. In the process, VaxGen's...
BioCentury | Apr 16, 2010
Company News

diaDexus, VaxGen to reverse-merge

...Diagnostic company diaDexus Inc. (South San Francisco, Calif.) will reverse-merge with VaxGen Inc. (OTCBB:VXGN) in a stock...
...shareholders will own 60.9% of the combined company, which will be known as diaDexus, with VaxGen...
...NYSE:EBS) related to VaxGen's rPA102 anthrax vaccine. Emergent acquired the vaccine in 2008. On Thursday, VaxGen...
BioCentury | Apr 5, 2010
Finance

Restructuring Watch

...ATC); a planned acquisition of VaxGen Inc. (OTCBB:VXGN) for about $22.2M in stock falls through after VaxGen...
BioCentury | Feb 15, 2010
Company News

OxiGene, VaxGen deal

...of VaxGen for about $22.2 million stock will not take place after a majority of VaxGen's...
...million against. A vote of 16.6 million in favor was required to approve the acquisition. VaxGen...
...assess other strategic alternatives (see BioCentury, Oct. 19, 2009). OxiGene Inc. (NASDAQ:OXGN; SSE:OXGN), Waltham, Mass. VaxGen Inc....
BioCentury | Oct 26, 2009
Finance

Ebb & Flow

...Corp. (NASDAQ: GENZ), the only marketed treatment for Fabry's disease in the U.S. Clinical milestones VaxGen Inc....
...III RV144 trial showed that ALVAC HIV vaccine from sanofi-aventis Group (Euronext:SAN; NYSE:SNY) boosted by VaxGen's...
BioCentury | Oct 26, 2009
Product Development

Correlates and Endpoints

...HIV, is from the non-profit Global Solutions for Infectious Diseases , which licensed it from VaxGen Inc....
...agencies" like the Bill & Melinda Gates Foundation , NIAID's Vaccine Research Center and IAVI. VaxGen...
...Genentech Inc. , a unit of Roche , to commercialize the vaccine in North America. VaxGen...
Items per page:
1 - 10 of 243